[go: up one dir, main page]

WO2024263803A3 - Nouveaux modulateurs de fshr et leurs utilisations - Google Patents

Nouveaux modulateurs de fshr et leurs utilisations Download PDF

Info

Publication number
WO2024263803A3
WO2024263803A3 PCT/US2024/034851 US2024034851W WO2024263803A3 WO 2024263803 A3 WO2024263803 A3 WO 2024263803A3 US 2024034851 W US2024034851 W US 2024034851W WO 2024263803 A3 WO2024263803 A3 WO 2024263803A3
Authority
WO
WIPO (PCT)
Prior art keywords
fshr
novel modulators
modulators
novel
fsh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/034851
Other languages
English (en)
Other versions
WO2024263803A2 (fr
Inventor
Stephen S. Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celmatix Inc
Original Assignee
Celmatix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celmatix Inc filed Critical Celmatix Inc
Publication of WO2024263803A2 publication Critical patent/WO2024263803A2/fr
Publication of WO2024263803A3 publication Critical patent/WO2024263803A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés modulateurs de FSH de formule (I) et des sels pharmaceutiquement acceptables de ceux-ci.
PCT/US2024/034851 2023-06-21 2024-06-20 Nouveaux modulateurs de fshr et leurs utilisations Pending WO2024263803A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363522292P 2023-06-21 2023-06-21
US63/522,292 2023-06-21

Publications (2)

Publication Number Publication Date
WO2024263803A2 WO2024263803A2 (fr) 2024-12-26
WO2024263803A3 true WO2024263803A3 (fr) 2025-05-01

Family

ID=93936387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034851 Pending WO2024263803A2 (fr) 2023-06-21 2024-06-20 Nouveaux modulateurs de fshr et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2024263803A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035356A2 (fr) * 2006-09-20 2008-03-27 Glenmark Pharmaceuticals Limited Nouveaux ligands de récepteur cannabinoïde, compositions pharmaceutiques les contenant, et procédé associé à leur préparation
US20100215741A1 (en) * 2009-02-25 2010-08-26 Neuroscienze Pharmaness S.C. A.R.L. Pharmaceutical compounds
WO2014209980A1 (fr) * 2013-06-24 2014-12-31 Merck Patent Gmbh Composés de pyrazole à titre de modulateurs de fshr et leurs utilisations
WO2015196759A1 (fr) * 2014-06-23 2015-12-30 Tocopherx, Inc. Composés de pyrazole utilisés en tant que modulateurs de fshr et leurs utilisations
WO2024044778A2 (fr) * 2022-08-26 2024-02-29 Celmatix Inc. Nouveaux modulateurs de fshr et leurs utilisations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035356A2 (fr) * 2006-09-20 2008-03-27 Glenmark Pharmaceuticals Limited Nouveaux ligands de récepteur cannabinoïde, compositions pharmaceutiques les contenant, et procédé associé à leur préparation
US20100215741A1 (en) * 2009-02-25 2010-08-26 Neuroscienze Pharmaness S.C. A.R.L. Pharmaceutical compounds
WO2014209980A1 (fr) * 2013-06-24 2014-12-31 Merck Patent Gmbh Composés de pyrazole à titre de modulateurs de fshr et leurs utilisations
WO2015196759A1 (fr) * 2014-06-23 2015-12-30 Tocopherx, Inc. Composés de pyrazole utilisés en tant que modulateurs de fshr et leurs utilisations
WO2024044778A2 (fr) * 2022-08-26 2024-02-29 Celmatix Inc. Nouveaux modulateurs de fshr et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Pubmed U.S. National Library of Medicine; 17 August 2024 (2024-08-17), ANONYMOUS: "Ethyl 3-(2,4-dichlorophenyl)-12-(3-fluoropropyl)-3,4-diazatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxylate", XP009563379, Database accession no. 134840788 *
PLESSIS ET AL.: "Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility", JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, vol. 32, 16 August 2015 (2015-08-16), pages 1575 - 1588, XP035912802, DOI: 10.1007/s10815-015-0553-8 *

Also Published As

Publication number Publication date
WO2024263803A2 (fr) 2024-12-26

Similar Documents

Publication Publication Date Title
EP4438122A3 (fr) Composé peptidique court à base de proline à cycle modifié et son utilisation
WO2021079196A3 (fr) Modulateurs de mettl3
ZA202410007B (en) Pyrimidine based modulators and uses thereof
MX2023014620A (es) Nuevos profarmacos y conjugados de dimetiltriptamina.
WO2002071827A3 (fr) Modulateurs des recepteurs x de retinoides
NO20051328L (no) Kalsiumreseptormodulerende forbindelse og anvendelse derav
WO2005103003A3 (fr) Inhibiteurs de l'enzyme integrase du vih
ATE184281T1 (de) 9-hydroxy-pyrido (1,2-a> pyrimidin-4-on-ether- derivate
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
CA3248327A1 (fr) Composés pyrrolidine
MX2025002166A (es) Compuestos y metodos para modular her2
WO2024123815A8 (fr) Procédé de synthèse de modulateurs de tétrahydrofurane substitués de canaux sodiques
MX2021011374A (es) Compuestos de heteroaril(heterocyclil)metanol útiles en el tratamiento de la hiperglucemia.
WO2024263803A3 (fr) Nouveaux modulateurs de fshr et leurs utilisations
WO2024254511A3 (fr) Inhibiteurs de wrn
MX2025000059A (es) Compuesto de sulfoximina con efecto inhibidor de fgfr, composicion farmaceutica que lo comprende y su uso
WO2022031862A3 (fr) Composés hétéroaryle et hétérocyclyle
WO2021226276A3 (fr) Modulateurs de nampt
WO2023147063A3 (fr) Composés et procédés de modulation de yap/tead et indications associées
WO2024044778A3 (fr) Nouveaux modulateurs de fshr et leurs utilisations
EP4545078A3 (fr) Composé benzo 2-azaspiro[4.4nonane et son utilisation
WO2022272036A9 (fr) Inhibiteurs de tead et leurs utilisations
WO2022234337A3 (fr) Dérivé de carbazole cristallin
MX2023006176A (es) Nuevos derivados de indazol acetileno.
WO2024036288A3 (fr) Agonistes inverses de gpr6

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24826664

Country of ref document: EP

Kind code of ref document: A2